Safety and Efficacy of the Use of pdVWF/FVIII-C in Patients with von Willebrand Disease : A Prospective, Observational, Post-Authorization Study
Benítez Hidalgo, Olga (Hospital Universitari Vall d'Hebron)
Marzo Alonso, C. (Hospital Universitari Arnau de Vilanova)
López Jaime, F.J. (Hospital Regional Universitario de Málaga)
Carrasco, Marina (Institut de Recerca Sant Pau)
Nieto Hernández, M.d.M. (Complejo Universitario de Jaén)
Afonso, N. (Scientific Innovation Office)
Lei, A. (Scientific Innovation Office)
Whyms, D. (Scientific Innovation Office)
Hanna, K. (Scientific Innovation Office)
Aragonés, M.E. (Scientific Innovation Office)
Torres, M. (Scientific Innovation Office)
Oliveras, Juan (Scientific Innovation Office)
Universitat Autònoma de Barcelona

Fecha:	2025
Resumen:	Introduction: Plasma-derived von Willebrand factor containing FVIII concentrates (pdVWF/FVIII-C) are indicated as replacement therapy for patients with von Willebrand disease (VWD). This study assessed safety and efficacy associated with long-term real-world experience of the pdVWF/FVIII-C, Fanhdi, in patients with VWD. Methods: This observational, prospective, post-authorization cohort study was conducted at five centers in Spain. Patients with VWD were treated with the pdVWF/FVIII-C to achieve satisfactory hemostasis for on-demand (bleeding episodes and surgical/invasive procedures) and prophylaxis treatment. Clinical efficacy was evaluated as the response to treatment in both settings. Safety parameters were assessed. Results: Fifteen VWD patients received at least one dose of the pdVWF/FVIII-C and were followed for 12 months. Forty-six bleeding episodes were reported for 9 (60. 0%) patients, and 6 surgical/invasive procedures for 5 (33. 3%) patients. Most frequently reported bleedings were gastrointestinal (3 [33. 0%] patients) and gynecological (3 [33. 0%] patients). No complications nor bleeding episodes related to surgical/invasive procedures were reported. Overall clinical efficacy of treatment (including on-demand and prophylaxis) achieved 100% excellent and/or good (n = 15 patients), being excellent for 7 (46. 7%) patients. There were 27 treatment-emergent adverse events in 8 (53. 3%) patients, 11 serious adverse events in 3 (20. 0%) patients, but none of them were drug-related. No clinical signs and symptoms of immunogenicity or thromboembolic events were reported. Conclusions: This real-world evidence study confirmed the efficacy of the pdVWF/FVIII-C as on-demand and/or prophylaxis treatment in patients with bleeding episodes or surgical procedures in VWD. Fanhdi was well tolerated without any safety concerns.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Bleeding ; Invasive procedures ; On-demand treatment ; Plasma-derived von Willebrand factor/factor VIII concentrate ; Prophylaxis treatment ; Real world evidence ; Surgery ; Von Willebrand disease
Publicado en:	Clinical and Applied Thrombosis/Hemostasis, Vol. 31 (1-12 2025) , ISSN 1938-2723

DOI: 10.1177/10760296251327593
PMID: 40079811

10 p, 315.4 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados